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Benzodiazepines and other omega-receptor agonists are
frequently used for sleep and anxiety disorders. We studied
the rates, correlates, and safety of individual benzodiazepines
and zolpidem use from the records of 3690 patients in a
national cohort of Dialysis Morbidity and Mortality Study
Wave 2 data. We assessed drug utilization and an association
between drug use and all-cause mortality. Overall, 14% of
incident dialysis patients used a benzodiazepine or zolpidem.
Women, Caucasians, current smokers, and patients with
chronic obstructive pulmonary disease were more likely to
use these drugs, whereas patients with cerebrovascular
disease were less likely to use these drugs. In adjusted
analyses, benzodiazepine or zolpidem use was associated
with a 15% higher mortality rate. Chronic obstructive
pulmonary disease significantly modified this association,
suggesting that these patients were at higher risk. No
association was found between benzodiazepine use and
greater risk for hip fracture. We conclude that
benzodiazepine or zolpidem use is common in incident
dialysis patients and may be associated with greater
mortality. Further studies are needed to elucidate the safety
of these drugs in the dialysis population, which may lead to
cautious and restrictive utilization of omega-receptor
agonists in dialysis patients.
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Benzodiazepines and the more recently developed non-
benzodiazepine omega-receptor agonists experience wide-
spread use in the general population, with sleep and anxiety
disorders being their main indications. Although 2–5% of
young adults use these medications, their use is particularly
high in older adults and in women.1–3 While clinically useful,
these medications may lead to an array of undesired
biological effects, such as dependency, withdrawal, rebound
symptoms, daytime sedation, confusion, cognitive deficits,
ataxia, dysarthria, diplopia, and vertigo.4 Serious adverse
drug events may be a consequence of these disturbances and
associations between benzodiazepine use and falls, major
fractures, and motor vehicle accidents have been reported,
especially in the elderly, whose elimination times of these
drugs may be prolonged.4–8
Several studies have demonstrated that sleep disorders are
common in chronic dialysis patients.9–11 Similarly, symptoms
of anxiety are also prevalent in these patients.12,13 Thus, one
could hypothesize that the use of benzodiazepines and related
substances might be rather common in dialysis patients.
Little is known, however, about the utilization patterns of
these drugs in US dialysis patients. Similar to elderly
populations, elimination of these drugs may be prolonged
in dialysis patients, placing them at high risk of adverse
events. Despite this, studies of the correlates of benzodiaze-
pine use and their safety in this vulnerable population are
lacking. Only one study of Japanese dialysis patients, where
these drugs are particularly widely used, indicated that
benzodiazepine use may be associated with an increased
mortality risk.14 Compared across countries, Japanese dialysis
patients have particularly high benzodiazepine use (19.2%)
and these drugs appear to serve as substitute for more well-
established treatments for clinical depression in that country.
Thus, it is unclear whether the findings from Japan are
generalizable. We conducted this study to address this issue.
We specifically sought to assess the rates and correlates of
benzodiazepine and other omega-receptor agonist use in a
representative sample of incident US dialysis patients.
Further, we studied the associations between the use of these
medications and important health outcomes in these
patients.
o r i g i n a l a r t i c l e http://www.kidney-international.org
& 2007 International Society of Nephrology
Received 11 April 2007; revised 29 June 2007; accepted 24 July 2007;
published online 12 September 2007
Correspondence: WC Winkelmayer, Division of Pharmacoepidemiology and
Pharmacoeconomics, Brigham and Women’s Hospital, 1620 Tremont Street,
Suite 3-030, Boston, Massachusetts 02120, USA.
E-mail: wwinkelmayer@partners.org
1388 Kidney International (2007) 72, 1388–1393
RESULTS
Cohort selection and characterization
Of the 4024 patients who initiated renal replacement therapy
in 1996–1997, 83 (2%) had their the US Renal Data System
(USRDS) identifier missing, 11 (0.3%) patients had duplicate
records, and 250 (6.2%) patients had evidence of dialysis or
transplantation before the dialysis start date listed in the
Dialysis Morbidity and Mortality Study (DMMS) Wave 2
files. Additionally, we excluded 50 (1.2%) patients for whom
all 15 medication fields were empty. The final study
population included 3630 patients. In 490 (13.5%) of these
patients, benzodiazepine or zolpidem was listed among their
abstracted medications; 435 had one, 53 had two, and 2
patients had three of these medications listed. Table 1
provides the counts and proportions of these medications:
temazepam (20%), lorazepam (19%), alprazolam (17%), and
clonazepam (13%) were the most frequently used benzodia-
zepines, and zolpidem represented 15% of such use.
Correlates of benzodiazepine or zolpidem use
Several patient characteristics differed between users and
nonusers of benzodiazepines or zolpidem (Table 2). Users
were older (60 vs 58 years, P¼ 0.005), more likely to be
female (53 vs 45%, P¼ 0.002), white (77 vs 60%, Po0.001),
and current smokers (18 vs 13%, P¼ 0.02). They were also
more likely to be married (57 vs 55%) or widowed/separated
(33 vs 29%) rather than single (10 vs 16%, P¼ 0.001). While
the presence of diabetes and hypertension was not associated
with benzodiazepine use, several other comorbid conditions
were, such as coronary artery disease, congestive heart failure,
peripheral vascular disease, chronic obstructive pulmonary
disease (COPD) (all Po0.001), and malignancy (P¼ 0.006).
No difference was found regarding patients’ educational
status, native kidney disease, or treatment modality. The
corresponding univariate odds ratios (ORs) and 95%
confidence intervals (CIs) can be found in Table 3. After
multivariate adjustment, we found that women were 46%
more likely to use benzodiazepines or zolpidem (OR¼ 1.46;
95% CI: 1.19–1.79), whereas blacks (OR¼ 0.48; 95% CI:
Table 1 | Frequency of benzodiazepine and zolpidem use in
study cohort (N=3630)
Generic substance N %
Benzodiazepines
Alprazolam 95 17.4
Chlordiazepoxidea 12 2.2
Clonazepama 69 12.6
Clorazepate 5 0.9
Diazepama 38 7.0
Estazolam 2 0.4
Flurazepama 16 2.9
Lorazepam 103 18.9
Oxazepam 5 0.9
Temazepam 110 20.2
Triazolam 9 1.7
Non-benzodiazepine omega-receptor agonists
Zolpidem 82 15.0
aAgents categorized as having long half-life.
Table 2 | Patient characteristics (N=3630)
Benzodiazepine or zolpidem
use
Variable %
Absent
(N=3140)
Present
(N=490) P-value
Age 58.3 (715.8) 60.4 (714.7) 0.005
Female gender 45.3 52.7 0.002
Race
White 59.8 76.5
Black 30.9 17.6
Other 9.3 5.9 o0.001
Hispanic ethnicity 11.5 10.8 0.65
Education
o12 years 30.3 29.2
High-school 30.2 33.5
Some college 15.4 14.3
College graduate 13.9 13.3
Missing 10.3 9.8 0.70
Marital status
Single 16.1 9.8
Married 54.8 57.1
Other 29.2 33.1 0.001
Smoker
Never 63.2 56.1
Past 24.0 26.3
Current 12.8 17.6 0.02
Diabetes 48.6 48.6 0.98
Hypertension 70.9 68.0 0.19
Coronary artery disease 35.5 45.9 o0.001
Congestive heart failure 35.3 44.7 o0.001
Cerebrovascular disease 10.0 7.6 0.09
Peripheral vascular disease 16.4 22.9 o0.001
Chronic obstructive pulmonary
disease
6.9 12.9 o0.001
History of cardiac arrest 1.3 2.7 0.03
Malignancy 7.6 11.2 0.006
Native kidney disease
Diabetic 43.7 41.8
Hypertensive 25.7 26.1
Glomerulonephritis 8.4 8.4
Other 22.1 23.7 0.85
Modalitya
Hemodialysis 54.7 56.9
Peritoneal dialysis 43.2 41.2
Unknown 2.1 1.8 0.61
Late nephrologist referral
(1386b)
33.9 31.2 0.37
Serum albumin (mg dl1)
(662b)
3.3 (70.7) 3.3 (70.6) 0.11
Hemoglobin (g dl1) (79b) 8.8 (74.6) 8.7 (75.6) 0.69
Serum creatinine (mg dl1)
(105b)
8.7 (73.7) 7.9 (73.4) o0.001
Systolic blood pressure
(mm Hg) (69b)
147 (725) 145 (725) 0.03
Diastolic blood pressure
(mm Hg) (68b)
80 (715) 79 (714) 0.04
aBy study design, peritoneal dialysis patients were oversampled by a 5:1 ratio
compared to hemodialysis patients.
bNumber of observations missing.
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0.37–0.62) or patients of other non-white/non-black races
(OR¼ 0.54; 95% CI: 0.36–0.83) were half as likely to
use these drugs compared with whites. Marital status
remained independently associated with benzodiazepine use
in that married (OR¼ 1.47; 95% CI: 1.02–2.12) and widowed
or separated patients (OR¼ 1.58; 95% CI: 1.08–2.30) were
more likely to use these medications compared to singles, as
were current smokers (vs never smokers; OR¼ 1.70; 95% CI:
1.28–2.26). Of all comorbid conditions, only two remained
independently associated with benzodiazepine or zolpidem
use: cerebrovascular disease was associated with lower use
(OR¼ 0.68; 95% CI: 0.47–0.98), whereas COPD was
associated with greater use (OR¼ 1.43; 95% CI: 1.03–1.98;
Table 3).
Clinical outcomes: all-cause mortality and hip fracture
During 11 081 person-years of follow-up, 1948 (53.7%)
patients died (176 deaths/1000 person-years). In univariate
analyses, benzodiazepine or zolpidem use was associated with
a 31% increase in mortality (hazards ratio (HR)¼ 1.31; 95%
CI: 1.15–1.48; Table 4). Multivariate adjustment attenuated
this apparent association, but the use of the study drugs
remained associated with a 15% increase in mortality risk
(HR¼ 1.15; 95% CI: 1.02–1.31). No differences were
apparent between short-acting and long-acting drugs or
between benzodiazepines and zolpidem (Table 4). When
testing for effect modification by various covariates, we found
that the risk of benzodiazepine use differed between patients
with COPD vs free from COPD (P(interaction)¼ 0.003). When
accounting for this effect modification, we found that
compared to similar nonusers, benzodiazepine users without
COPD had no elevated mortality risk, whereas those dialysis
patients who also suffered from COPD had a significant 67%
increase in mortality risk (OR¼ 1.67; 95% CI: 1.19–2.34).
As expected, hip fracture was a relatively rare event in this
population, experienced by 68 patients (1.9%) during follow-
up (6.2 events/1000 person-years). In univariate associations,
benzodiazepine or zolpidem use was not associated with a
greater risk of hip fracture (HR¼ 1.38; 95% CI: 0.71–2.70).
After adjustment for the exposure propensity score
(c¼ 0.66), this association remained absent (OR¼ 1.00;
95% CI: 0.50–1.97). Unadjusted analyses that used separate
Table 3 | Correlates of benzodiazepine or zolpidem use
Variable
Univariate Multivariate
Odds
ratio 95% CI
Odds
ratio 95% CI
Age (years)
p45 1.0 Referent 1.0 Referent
445–65 1.14 0.87–1.50 0.86 0.64–1.17
465 1.41 1.08–1.84 0.90 0.65–1.24
Female gender (vs male) 1.34 1.11–1.63 1.46 1.19–1.79
Race
White 1.0 Referent 1.0 Referent
Black 0.44 0.35–0.57 0.48 0.37–0.62
Other 0.50 0.33–0.74 0.54 0.36–0.83
Hispanic ethnicity 1.07 0.79–1.46 1.04 0.75–1.44
Education
o12 years 1.0 Referent 1.0 Referent
High-school 1.15 0.90–1.46 1.09 0.85–1.41
Some college 0.96 0.71–1.31 1.04 0.75–1.43
College graduate 0.99 0.73–1.36 1.05 0.75–1.46
Missing 0.98 0.69–1.40 0.96 0.67–1.38
Marital status
Single 1.0 Referent 1.0 Referent
Married 1.71 1.24–2.36 1.47 1.02–2.12
Other 1.86 1.32–2.61 1.58 1.08–2.30
Smoker
Never 1.0 Referent 1.0 Referent
Past 1.23 0.99–1.55 1.07 0.84–1.37
Current 1.54 1.18–2.01 1.70 1.28–2.26
Diabetes 1.00 0.83–1.21 0.93 0.75–1.14
Hypertension 0.87 0.71–1.07 0.86 0.69–1.06
Coronary artery disease 1.54 1.27–1.87 1.19 0.97–1.54
Congestive heart failure 1.48 1.22–1.79 1.22 0.97–1.52
Cerebrovascular disease 0.74 0.52–1.05 0.68 0.47–0.98
Peripheral vascular disease 1.51 1.20–1.90 1.28 0.99–1.65
Chronic obstructive
pulmonary disease
2.00 1.48–2.69 1.43 1.03–1.98
History of cardiac arrest 2.01 1.07–3.77 1.61 0.84–3.11
Malignancy 1.54 1.13–2.09 1.32 0.95–1.83
Modality
Hemodialysis 1.0 Referent 1.0 Referent
Peritoneal dialysis 0.92 0.75–1.11 0.86 0.70–1.06
Unknown 0.83 0.41–1.68 1.01 0.48–2.15
CI, confidence interval.
Table 4 | Benzodiazepine or zolpidem use and all-cause
mortality
Variable
Univariate Multivariate
HR 95% CI HR 95% CI
Benzodiazepine or zolpidem
Non users 1.0 Referent 1.0 Referent
Users 1.31 1.15–1.48 1.15 1.02–1.31
Non users 1.0 Referent 1.0 Referent
1 drug 1.29 1.14–1.47 1.13 0.99–1.29
41 drug 1.41 1.00–1.98 1.40 0.99–1.98
Non users 1.0 Referent 1.0 Referent
Short-acting 1.34 1.17–1.54 1.17 1.02–1.35
Long-acting 1.21 0.97–1.52 1.11 0.88–1.39
Benzodiazepines vs zolpidem
Non users 1.0 Referent 1.0 Referent
Benzodiazepine users 1.28 1.12–1.46 1.15 1.00–1.31
Zolpidem users 1.44 1.09–1.91 1.18 0.89–1.56
Test for effect modification by diagnosed chronic obstructive pulmonary
disease in the multivariate model: P=0.003
Benzodiazepine or zolpidem by history of COPD
Non users 1.0 Referent
Users without COPD 1.07 0.93–1.23
Users with COPD 1.67 1.19–2.34
CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazards
ratio.
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variables for benzodiazepines vs zolpidem suggested that
benzodiazepine use was not associated with hip fracture risk
(HR¼ 0.87; 95% CI: 0.38–2.02), whereas zolpidem users had
more than triple the risk of hip fracture (HR¼ 3.26; 95% CI:
1.18–8.98) compared to nonusers of zolpidem or benzodia-
zepines. This latter association persisted after age and sex
adjustment (OR¼ 3.01; 95% CI: 1.09–8.29). Due to the small
number of both zolpidem users and outcomes, neither more
detailed multivariate methods nor propensity methods could
be employed.15 However, a recent study has demonstrated
that age and sex were sufficient in predicting future risk of
hip fracture in prevalent dialysis patients: the c-statistic of a
model using just these two variables was 0.69 compared to
c¼ 0.71 of a model that included a large number of
additional clinical and laboratory characteristics.16
All results remained robust whether or not we censored for
receipt of a kidney transplant, included additional information
about functional status at baseline, or whether we used
multivariate or propensity score-adjusted outcome models.
DISCUSSION
In a nationally representative cohort of dialysis patients, we
found a high prevalence of benzodiazepine or non-benzo-
diazepine omega-receptor agonist use (13.7%). This rate is
similar to the rate reported in the Dialysis Outcomes and
Practice Patterns Study II (17.2% in prevalent dialysis
patients from all participating countries), but lower than in
the recent study of benzodiazepine use and mortality from
Japan (19.2%).14,17 Similar to the recent study by Fukuhara
et al.,14 we found an association between benzodiazepine use
and all-cause mortality. Replication of their finding appeared
important for several reasons: first, benzodiazepines are used
more frequently in Japan compared to most other countries,
and these drugs appeared to be channeled toward patients
with depressive symptoms, whose diagnosis by a physician or
treatment with antidepressants was particularly infrequent in
that country. Depression, in turn, is a risk factor for
mortality. Second, the Japanese study used prevalent patients,
whereas we used a nationally representative sample of
incident dialysis patients. Third, the earlier findings of an
association between benzodiazepine use and mortality were
of borderline significance (HR¼ 1.27; 95% CI: 1.01–1.59—as
are our own findings: HR¼ 1.15; 95% CI: 1.02–1.31), and
hence seemed important to confirm this association in an
independent population.
Although age was not an independent predictor in our
study, men and individuals of non-white race were less likely
to use these drugs. Patients with a history of cerebrovascular
disease had lower rates of benzodiazepine use; reducing use
in such a population may be clinically appropriate, given the
potential of this medication class to exacerbate the confusion,
impaired cognition, ataxia, dysarthria, diplopia, vertigo, and
other deficits associated with central nervous system condi-
tions.18
By contrast, we found that patients diagnosed with COPD
had a nearly 50% increased use of benzodiazepines or
zolpidem compared to patients without this condition.
Reasons for the greater use in this population are unclear,
but one possibility is that these medications are being used to
treat the anxiety symptoms and disrupted sleep associated
with respiratory insufficiency. Regardless of the reasons, such
increased utilization of benzodiazepines by patients with
COPD is worrisome because these medications can depress
central nervous activity including respiratory drive.19–28 In
fact, we found that COPD was an effect modifier of the
association between benzodiazepine use and mortality:
although patients without COPD who used benzodiazepines
had similar mortality to patients without such drug
treatment, the data suggested that COPD patients who used
these drugs may be at an increased risk of mortality. While we
could not establish a causal association from this observa-
tional study, these findings arose from carefully adjusted
analyses and point toward a potentially important drug safety
issue in the treatment of these patients with benzodiazepines
or other omega-receptor agonists. We are aware of only one
study that has evaluated the association between benzodia-
zepine use and mortality in dialysis patients. In Japan,
patients who received benzodiazepines had an adjusted 31%
increased mortality compared to nonusers (P¼ 0.03),14
which is compatible with our findings of a 15% increase in
mortality risk. That Japanese study, however, did not evaluate
effect modification by COPD status.
Sleep disturbances and anxiety are rather prevalent in
dialysis patients. Unruh et al.11 demonstrated that, compared to
similar control patients, dialysis patients have greater trouble
falling asleep, maintaining their sleep, and falling asleep again
after waking up. Fewer dialysis patients than controls felt rested
in the morning. Correlated with these sleeping patterns, or as a
consequence of it, dialysis patients were more likely to feel
drowsy during the day, had trouble staying awake, and were
more likely to take naps during the day.11 While benzodiaze-
pines are certainly effective in treating some sleep disorders,
additional concerns about their chronic use have been raised
including dependency, withdrawal, rebound symptoms, day-
time sedation, falls, and fractures; these concerns may be even
greater in certain populations with reduced metabolization or
elimination of these drugs, such as the elderly or those with
renal impairment.4,29 For this reason, studies of the safety of
these drugs in these vulnerable, high-risk populations are
especially important.
Associations between benzodiazepine use and injuries
have been reported, both in the elderly and in one study of
dialysis patients.4,5,17 Several psychotropic medication classes
have been shown to increase the risk of fractures, benzodia-
zepines being one of them.4 Studies have been inconclusive
regarding possible risk differences by elimination half-life.
Zolpidem use has also recently been linked to an increased
risk of hip fractures in older patients, with a risk that is at
least similar to benzodiazepines: zolpidem was associated
with a doubling of fracture risk compared to nonusers,
whereas benzodiazepines conferred a 50% greater risk.30 Our
findings suggest that zolpidem may be similarly risky in
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dialysis patients, with an observed three-fold hip fracture risk
compared to nonusers in age- and sex-adjusted analyses.
Benzodiazepine use was not independently associated with
the risk of hip fractures, which is compatible with recent data
from DOPPS II.17 Regardless of benzodiazepine or zolpidem
use, dialysis patients are at an increased risk of fractures,
likely as a consequence of their chronic disturbances of bone
metabolism and the circulatory instabilities that come with
intermittent removal of fluids.31 Thus, any agent causing
more falls may be implicated in contributing to greater
morbidity and mortality in these patients.
From a pharmacoepidemiological methods perspective,
this study has certain weaknesses. Use of the study drugs was
ascertained at a single point in time. Therefore, we limited
follow-up to the year 2000, although the USRDS data are
now available through 2004. No information was available on
the dose and duration of treatment, or whether the drug was
meant to be taken regularly or on an as-needed basis. While
this is a cohort of incident dialysis patients, it is not an
inception cohort with regard to benzodiazepine use.
Furthermore, ascertainment of drug exposure from records
may not reflect actual use by the patient. Since patients were
not randomly assigned to the treatment drugs, it is possible
that residual confounding exists, specifically that other
prognostic characteristics beyond the ones observed in this
study differed between the exposure categories (confounding
by indication). Unfortunately, several other variables in the
study data set were missing in the majority of patients. This
included information on depression, functional status,
transportation to dialysis, and cause of death. Finally, we
tested for all possible interactions and the only one we found
(with COPD) was significant at P¼ 0.003; it is possible that
this is a chance finding, a fallacy from multiple testing. These
limitations need to be considered in light of the study’s
strengths. The study population constitutes a nationally
representative sample of incident dialysis patients and
permits generalizability. The nature of the USRDS as being
drawn from these patients’ Medicare claims yields near-
complete follow-up. The study used definitive end points
such as death, and our approach to identify a hip fracture has
previously been validated in claims data.32 The results of this
study remained robust and were not influenced by the use of
propensity scores, censoring for transplantation, or when
patient’s ability to ambulate (missing in 79 patients, results
not shown) was taken into account.
While it is unclear whether the reported associations reflect
causal relationships, this study points toward a potentially
important safety issue with benzodiazepine use in dialysis
patients. In addition, from our literature review, we found a
striking absence of studies on the safety and appropriate
dosing of these drugs in dialysis patients. Whether the excess
mortality seen in users of benzodiazepines or zolpidem is
restricted to patients with a comorbid condition of COPD or
rather affects all dialysis patients needs to be determined.
Regarding this and the observed increased hip fracture risk
with zolpidem use, future studies are needed to confirm and
further refine our understanding of these relationships.
Certainly, residual confounding remains a potential problem
in such pharmacoepidemiological studies. Ultimately, how-
ever, only randomized controlled trials have the capacity to
settle this issue. In the meanwhile, cautious and restrictive use
of these agents in dialysis patients appears prudent.
MATERIALS AND METHODS
Study population and follow-up
The DMMS Wave 2 was a special study conducted by the USRDS. In
1996–1997, dialysis facilities were randomly selected and all their
patients who began peritoneal dialysis and a random 20% sample of
all incident hemodialysis patients were prospectively enrolled for
study (N¼ 4024). Data on earlier medical history, demographics,
and medications were obtained from patient records. Baseline data
were collected at approximately 60 days after first renal replacement
therapy. Follow-up questionnaires were administered 9–12 months
after enrollment, and data collection was completed in 1999. Patient
follow-up is available through the USRDS core data set; all records
can be linked to any given patient using the unique identifier
assigned by USRDS. For this study, we used year 2000 USRDS files.
No personally identifiable data were used in any analyses.
From the overall DMMS Wave 2 sample, we excluded patients
who did not have a USRDS-assigned identifier, patients for whom
information on medication use was completely missing, and
patients who were not truly incident as evident from receipt of
maintenance dialysis or kidney transplantation before the DMMS
Wave 2 enrollment period.
Main exposures
The main exposure variables were obtained from the patient
questionnaire portion of DMMS Wave 2. Medications were
manually noted by study personnel and up to 15 different
medications could be listed. We abstracted all medication fields
and translated these entries into a database of consistent generic
substance names. For the purpose of this study, we specifically
sought to identify patients who used any benzodiazepine or
zolpidem, the only non-benzodiazepine omega-receptor agonist
that was marketed at the time of study enrollment.
For secondary analyses, we also separated these medications into
long-acting agents (diazepam, flurazepam, chlordiazepoxide, and
clonazepam) and agents of shorter half-life (alprazolam, clorazepate,
estazolam, lorazepam, oxazepam, temazepam, triazolam, or zolpi-
dem).4 We also noted the number of distinct medications from this
list that were noted for each patient.
Other patient characteristics
For each patient, we identified several demographic and socio-
economic characteristics: age at first dialysis (continuous), gender
(female, male), race (white, black, other), Hispanic ethnicity (yes/
no), socioeconomic characteristics (education, marital status, living
alone), and presence of several comorbidities (all yes/no). Comorbid
conditions were abstracted from patient records and included
diabetes, hypertension, coronary heart disease, congestive heart
failure, peripheral artery disease or amputation, cerebrovascular
disease, COPD, history of cardiac arrest, and any malignancy. We
also ascertained the initial dialysis modality chosen (center
hemodialysis, continuous ambulatory peritoneal dialysis, other).
Several vital and laboratory parameters were also available from
medical evidence files (serum creatinine, hemoglobin, calcium,
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phosphorus, albumin concentrations, and systolic and diastolic
blood pressure).
Outcomes
The primary outcome of the study was mortality from any cause as
reported by USRDS. A secondary outcome was hospitalization for
hip fracture, ascertained by the presence of a discharge diagnosis or
a procedure code representing surgical repair of a hip fracture. Such
a claims based approach to identifying hip fractures has been shown
to possess a positive predictive value of 98%.32
Statistical analyses
All statistical analyses were preformed using SAS version 9.1 (SAS
Institute, Cary, NC). We compared the characteristics of patients who
used benzodiazepines or other omega-receptor agonists, using paired
t-tests and w2-test. We used simple and multivariate logistic
regression to identify the crude and independent associations
between the observed patient characteristics and use of the study
drugs. Results were expressed as ORs and 95% CIs. Further we
assessed the independent association between any benzodiazepine or
other omega-receptor agonist use and all-cause mortality using
multivariate Cox proportional hazards regression; multivariate
models included all covariates regardless of any significant threshold.
Patients were followed from first dialysis to their death or end of
follow-up (30 September 2000, at which point they were censored).
Additional analyses censored at receipt of a kidney transplant. A
similar approach was used for the outcome of hip fracture; patients
were censored at death or end of follow-up. Since this outcome was
expected to be a relatively rare occurrence, we sought to estimate each
patient’s propensity score to receive a benzodiazepine or zolpidem
using a multivariate logistic regression model. This model included
all variables described above. The propensity score was then used as a
linear (continuous) covariate in a bivariate Cox regression model of
time to first hip fracture, together with the main exposure variable.
Propensity score analyses are particularly useful in settings where the
exposure is relatively common, but the outcome is rare.15 We also
sought to evaluate the association with hip fracture for benzodiaze-
pines and zolpidem separately, since zolpidem has been incriminated
with a greater hip fracture risk in the general population.30
In all multivariate Cox regression models, we tested for
interactions between the main exposure variable and all other
covariates and tested for violations of the proportionality assump-
tion using interactions with follow-up time. As measures of
association, we estimated HRs and their 95% CIs.
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